肿瘤相关性贫血研究进展  

Research progress of cancer related anemia

作　　者：尉慧凯 安宁[2] 张献清[2] 胡兴斌[2] 

机构地区：[1]第四军医大学航空医学系,西安710032 [2] 第四军医大学西京医院输血科

出　　处：《国际肿瘤学杂志》2015年第3期238-240,共3页Journal of International Oncology

基　　金：陕西省科学技术研究发展计划项目（2014K11-03--06-06）

摘　　要：肿瘤相关性贫血（ CRA）是肿瘤的常见并发症，尤其在接受放化疗的肿瘤患者中其发病率超过70%。CRA可以引起很多临床症状，同时对肿瘤治疗效果具有严重的负作用，所以它是严重危害肿瘤患者生命质量的因素之一。现有的CRA临床治疗措施，如输血、重组促红细胞生成素治疗和铁剂补充等都可以在一定程度上纠正和改善CRA的临床症状。但是由于CRA致病因素复杂多样，现有的临床治疗方案在治疗效果和使用安全上都存在局限性。因此CRA治疗亟待更为安全有效的治疗措施。Cancer related anemia（ CRA）is one of the ancer complications. The incidence rate of CRA is more than 70% in patients after receiving chemotherapy,radiation therapy,or both. CRA has severe clinical symptoms which significantly attenuate effectiveness of cancer treatment and the quality of patients＆#39; life. The current treatments for CRA,such as transfusion,recombinant EPO therapy,iron supplement and so on,could correct CRA in some sense. However,the present accepted therapeutic approaches could not be satisfied since there are complexity and diversity factors accounting for CRA. More effective and safety treatments of CRA are required in the near future.

关 键 词：肿瘤 贫血 红细胞生成素 

分 类 号：R730.5[医药卫生—肿瘤]